Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

702 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N. Nagai T, et al. Among authors: usui n. Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25. Int J Hematol. 2010. PMID: 20577839 Clinical Trial.
Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia.
Ohnishi K, Ino A, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga M, Hotta T, Ohno R; Japan Adult Leukemia Study Group. Ohnishi K, et al. Among authors: usui n. Int J Hematol. 2004 May;79(4):345-53. doi: 10.1532/ijh97.03160. Int J Hematol. 2004. PMID: 15218963 Clinical Trial.
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R; Japan Adult Leukemia Study Group. Yanada M, et al. Among authors: usui n. J Clin Oncol. 2006 Jan 20;24(3):460-6. doi: 10.1200/JCO.2005.03.2177. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344315 Clinical Trial.
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sakamaki H, Ishizawa KI, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R. Sakamaki H, et al. Among authors: usui n. Int J Hematol. 2009 Apr;89(3):332-341. doi: 10.1007/s12185-009-0260-2. Epub 2009 Mar 5. Int J Hematol. 2009. PMID: 19263190 Clinical Trial.
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R. Kobayashi Y, et al. Among authors: usui n. Int J Hematol. 2009 May;89(4):460-469. doi: 10.1007/s12185-009-0298-1. Epub 2009 Apr 10. Int J Hematol. 2009. PMID: 19360457 Clinical Trial.
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. Tojo A, et al. Among authors: usui n. Int J Hematol. 2009 Jun;89(5):679-88. doi: 10.1007/s12185-009-0327-0. Epub 2009 May 19. Int J Hematol. 2009. PMID: 19449194 Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: usui n. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R. Jinnai I, et al. Among authors: usui n. Int J Hematol. 2010 Oct;92(3):490-502. doi: 10.1007/s12185-010-0672-z. Epub 2010 Sep 10. Int J Hematol. 2010. PMID: 20830614 Clinical Trial.
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R. Kobayashi Y, et al. Among authors: usui n. Int J Hematol. 2011 Jun;93(6):745-749. doi: 10.1007/s12185-011-0864-1. Epub 2011 May 20. Int J Hematol. 2011. PMID: 21594763
702 results